Immune checkpoint inhibitors: A breakthrough for immunotherapy

Immune checkpoint inhibitors (ICIs) have shown their efficacy, not only as a standalone treatment, but also when combined with traditional methods like chemotherapy and radiation. However, persistent challenges such as high costs and regulatory hurdles still exist. Gain expert knowledge on this novel approach to cancer therapy, with key topics including:

  • Clinical trial landscape in 2023
  • SWOT analysis of ICIs
  • Challenges around high costs and toxicity
  • Future trends, including the potential of PD-1 inhibitors


Sign up to our content service and access now

  • Please select...

Opt In?